TLDR Early treatment of Folliculitis Decalvans in children can improve inflammation and partially regrow hair.
This case series investigates three pediatric cases of Folliculitis Decalvans, a rare inflammatory scalp disorder causing cicatricial alopecia. It highlights the clinical, trichoscopic, and histopathological features of FD in children, noting the involvement of methicillin-resistant Staphylococcus aureus infections. Treatment with antibiotics, dapsone, and cetrimide shampoo led to significant improvement in inflammation and partial hair regrowth over 16 weeks. The study emphasizes the rarity and therapeutic challenges of pediatric FD and the importance of early intervention to prevent permanent hair loss.
40 citations
,
August 2018 in “Journal of the American Academy of Dermatology” Clindamycin and rifampicin are the most effective treatments for folliculitis decalvans, but more research is needed.
41 citations
,
June 2018 in “Journal of The American Academy of Dermatology” Some treatments for folliculitis decalvans work well, with tetracyclines and a mix of rifampicin and clindamycin being most effective.
39 citations
,
July 2000 in “British Journal of Dermatology” Identical twins both had a rare hair loss condition, suggesting it might be genetic.
1 citations
,
January 2022 in “Skin appendage disorders” DCPA is a chronic skin condition affecting the legs, often misdiagnosed, and needs more research for better understanding and treatment.
November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
January 2025 in “Annals of Dermatology” PCA patients have more harmful bacteria and antibiotic resistance, needing specific testing for treatment.
3 citations
,
January 2024 in “Cureus” Folliculitis decalvans was successfully treated with doxycycline and ozenoxacin.